Accessibility Menu
 
Syndax Pharmaceuticals logo

Syndax Pharmaceuticals

(NASDAQ) SNDX

Current Price$24.20
Market Cap$2.14B
Since IPO (2016)+102%
5 Year+6%
1 Year+72%
1 Month+20%

Syndax Pharmaceuticals Financials at a Glance

Market Cap

$2.14B

Revenue (TTM)

$172.35M

Net Income (TTM)

$285.42M

EPS (TTM)

$-3.30

P/E Ratio

-7.35

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$24.20

Volume

65,710

Open

$24.00

Previous Close

$24.20

Daily Range

$23.98 - $25.42

52-Week Range

$8.58 - $25.44

SNDX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Syndax Pharmaceuticals

Industry

Biotechnology

Employees

298

CEO

Michael A. Metzger, MBA

Headquarters

New York City, MA 02451, US

SNDX Financials

Key Financial Metrics (TTM)

Gross Margin

96%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-162%

Return on Capital

-67%

Return on Assets

-54%

Earnings Yield

-13.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.14B

Shares Outstanding

88.20M

Volume

65.71K

Short Interest

0.00%

Avg. Volume

1.31M

Financials (TTM)

Gross Profit

$165.38M

Operating Income

$273.08M

EBITDA

$251.64M

Operating Cash Flow

$322.98M

Capital Expenditure

$187.00K

Free Cash Flow

$323.17M

Cash & ST Invst.

$394.07M

Total Debt

$346.48M

Syndax Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$68.48M

+791.7%

Gross Profit

$70.05M

+812.1%

Gross Margin

1.02%

N/A

Market Cap

$2.14B

N/A

Market Cap/Employee

$7.92M

N/A

Employees

270

N/A

Net Income

$68.01M

+27.8%

EBITDA

$15.31M

+82.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$47.59M

-79.9%

Accounts Receivable

$38.00M

+173.9%

Inventory

$32.75M

+8849.2%

Long Term Debt

$346.01M

+3.9%

Short Term Debt

$472.00K

-96.3%

Return on Assets

-53.88%

N/A

Return on Invested Capital

-66.67%

N/A

Free Cash Flow

$69.54M

-21.2%

Operating Cash Flow

$69.49M

-21.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RLAYRelay Therapeutics, Inc.
$9.91-0.90%
NKTRNektar Therapeutics
$72.22-3.50%
IMTXImmatics N.V.
$9.43-2.88%
AMLXAmylyx Pharmaceuticals, Inc.
$13.81-1.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
TAT&T
$28.31+0.02%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About SNDX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.